GSK reaches $2.2bn heartburn medication Zantac settlement in US
GSK has reached a $2.2bn settlement to resolve the vast majority of cases linked to its heartburn medicine Zantac, in a move that will help assuage legal concerns overhanging the UK drugmaker. The company said on Wednesday it had reached agreements with 10 plaintiff firms representing around 80,